Scarica l'app Stockscreener
19.46
2.65%
-0.53
Dopo l'orario di chiusura:
19.45
-0.01
-0.05%
Panoramica
Notizia
Cronologia dei prezzi
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$19.99
Aprire:
$19.65
Volume 24 ore:
233.13K
Relative Volume:
0.70
Capitalizzazione di mercato:
$722.88M
Reddito:
$11.88M
Utile/perdita netta:
$-162.08M
Rapporto P/E:
-1.5588
EPS:
-12.484
Flusso di cassa netto:
$-156.43M
1 W Prestazione:
-4.61%
1M Prestazione:
+12.29%
6M Prestazione:
+55.06%
1 anno Prestazione:
+59.12%
Intervallo 1D:
$19.16
$19.89
Intervallo di 1 settimana:
$19.16
$21.53
Portata 52W:
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
Nome
Crescent Biopharma Inc
Settore
Industria
Telefono
617-430-5595
Indirizzo
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
19.46 | 742.57M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Piper Sandler | Overweight |
| 2026-01-21 | Iniziato | Guggenheim | Buy |
| 2025-08-25 | Iniziato | Jefferies | Buy |
| 2025-08-11 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-14 | Iniziato | Wedbush | Outperform |
| 2025-06-25 | Iniziato | Stifel | Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-11 | Iniziato | Noble Capital Markets | Outperform |
| 2024-07-26 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-22 | Iniziato | CapitalOne | Overweight |
| 2021-11-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-04-29 | Ripresa | Stephens | Overweight |
| 2021-02-10 | Iniziato | Piper Sandler | Overweight |
| 2020-05-21 | Iniziato | Raymond James | Outperform |
| 2019-11-14 | Iniziato | ROTH Capital | Buy |
| 2019-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-05 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-04 | Iniziato | Oppenheimer | Outperform |
| 2018-12-18 | Iniziato | H.C. Wainwright | Buy |
| 2018-02-12 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Reiterato | Chardan Capital Markets | Buy |
| 2017-12-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Iniziato | Chardan Capital Markets | Buy |
| 2017-06-06 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-07-26 | Iniziato | SunTrust | Buy |
| 2016-06-30 | Iniziato | Rodman & Renshaw | Buy |
| 2015-03-17 | Reiterato | Stifel | Buy |
Mostra tutto
Crescent Biopharma Inc Borsa (CBIO) Ultime notizie
CBIO: Major clinical milestones and global expansion set for 2027, with key data and partnerships advancing - TradingView
Crescent Biopharma at Cantor conference: global trial push By Investing.com - Investing.com Canada
Crescent Biopharma at Cantor conference: global trial push - Investing.com
Two employees receive options tied to 58,650 Crescent Biopharma shares - Stock Titan
Crescent Biopharma (CBIO) Surges 8.9% to $20.20 as Biotech Momentum BuildsIV Contraction - vinanet.vn
Crescent Biopharma Announces September 2026 Investor Conference Presentations - Quiver Quantitative
Crescent Biopharma to Present at September Investor Conferences - GlobeNewswire
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Balyasny Asset Management L.P. Expands Stake in Crescent Biophar - GuruFocus
Crescent Biopharma (NASDAQ:CBIO) Stock Price Up 4.9%Should You Buy? - MarketBeat
Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Gap DownShould You Sell? - MarketBeat
Crescent Biopharma (CBIO) Shares Dip 2.86% as Stock Approaches Key $16 Support LevelDeath Cross - dars.gov.et
Crescent Biopharma Ord Shs (CBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CBIO Q2 2026 Earnings: Narrower-Than-Expected Loss Buoys SharesRevenue Miss Report - vinanet.vn
Q3 EPS Forecast for Crescent Biopharma Lowered by Analyst - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
CRESCENT BIOPHARMA, INC. SEC Filing (Aug 3, 2026) - Stock Titan
Perceptive Advisors LLC Lowers Stake in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma (CBIO) Gets a Buy from Wedbush - The Globe and Mail
Crescent Biopharma Announces Q2 2026 Financial Results and Operational Update - Kalkine Media
Crescent Biopharma Reports Q2 2026 Results and Advances Clinical Development of CR-001, CR-002 and CR-003 - Quiver Quantitative
Crescent Biopharma: Q2 Earnings Snapshot - KING5.com
Crescent Biopharma posts $24.8 million Q2 net loss - Quiver Quantitative
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
CBIO Q1 2026 Earnings: EPS Beat Despite Pre-Revenue Status; Stock DeclinesEPS Guidance Update - vinanet.vn
Crescent Biopharma Ord Shs (CBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Crescent Biopharma Market Sentiment - Benzinga España
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Crescent Biopharma Ord Shs (CBIO) Institutional Confidence - TradingKey
CBIO Q1 2026 Earnings: Narrower Loss Surprises Analysts as Cash Management ImprovesEarnings Quality Score - vinanet.vn
CBIO|Crescent Biopharma Ord Shs|Price:16.300|Chg%:-0.730 - TradingKey
Crescent Biopharma (CBIO) Shares Dip 4.3% as Stock Pulls Back Toward Key SupportDefined Outcome ETF - dars.gov.et
Crescent Biopharma grants inducement stock options for 52,500 shares at $15.83 each - Bitget
Two Crescent Biopharma Employees Receive 52,500 Stock Options - Stock Titan
CBIO Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers Positive Surprise as Pipeline Progress ContinuesRevenue Inflection Point - vinanet.vn
CBIO Options Volatility — NASDAQ:CBIO - TradingView
Jennison Associates LLC Invests $2.81 Million in Crescent Biopharma, Inc. $CBIO - MarketBeat
Fairmount Healthcare Fund II LP acquires 853,450 Crescent Biopharma shares for $12.38 million - Bitget
Fairmount Funds' $12 Million Bet on Crescent Biopharma: A Strong Signal Amidst Volatility - Kavout | AI
Insider fund at Crescent Biopharma (NASDAQ: CBIO) buys 1.38M shares, warrants - Stock Titan
Fairmount Funds holds 16.5% of Crescent Biopharma (CBIO) after July 2026 deal - Stock Titan
CBIO Q1 2026 Earnings: Better-than-Expected Loss as Biotech Continues DevelopmentInvestor Earnings Call - vinanet.vn
CBIO Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates Amid R&D ProgressBasic EPS Analysis - vinanet.vn
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma (CBIO) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Crescent Biopharma closes $143.7 million public offering - Investing.com
Crescent Biopharma closes $143.7 million public offering By Investing.com - Investing.com Nigeria
Crescent Biopharma (CBIO) Proxy filing Summary - Quartr
Crescent Biopharma Inc Azioni (CBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):